Are You CCBHC Ready? Preparing for the 2026 SAMHSA Funding Cycle is starting in

Journal Retracts Study On Leucovorin As Autism Treatment Cited In Federal Policy Announcement

On January 29, 2026, the European Journal of Pediatrics retracted a study evaluating leucovorin (folinic acid) as a treatment for autism spectrum disorder, citing errors in the analysis and concerns regarding the accuracy of the reported results.

The retracted study, Efficacy of Oral Folinic Acid Supplementation in Children with Autism Spectrum Disorder: A Randomized Double-Blind, Placebo-Controlled Trial, had been referenced in a September 22, 2025 federal announcement regarding autism policy.

In the retraction notice, the journal editor reported apparent errors in Tables 2 and 3 and concerns with the statistical analyses. A post-publication statistical review was unable . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.